Brief: Cleveland Biolabs announces commencement of in Vivo Biocomparability study

Statera Biopharma

17/04/2017 12:38

April 17 (Reuters) - Cleveland Biolabs Inc  CBLI.O  
    * Cleveland Biolabs announces commencement of in Vivo 
biocomparability study 
    * FDA provided CBLI with its consent for initiation of an in 
Vivo Biocomparability study of the formulations in non-human 
primates 
    * Planned biocomparability study is funded in part by 
department of defense joint Warfighter Medical Research Program 
contract 
    * FDA completed its review of a side-by-side analytical 
comparison of two formulations of entolimod 
 
Source text for Eikon:  ID:nMKWjXj4Ya  
Further company coverage:  CBLI.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))